Håkan Billig, Chair, University of Gothenburg
Anna Sandström, AstraZeneca
Maria Jenmalm, Linköping University
Nina Herne, Herne Consulting AB
Peter Nygren, Uppsala University
Rolf Karlsten, Uppsala University
Tomas Lundqvist, Camfil AB
Platform Advisory Board (PAB)
Claes Wahlestedt Chair, 2024 – Director, Center for Therapeutic Innovation (CTI), University of Miami, US
Fiona Marshall – President of the Novartis Institutes for BioMedical Research, US
Justin Bryans – CSO at Charles River Laboratories, UK
Lorenz Mayr – Mayr BioMedTech Consulting, CH
Lovisa Afzélius – General Partner, Flagship Pioneering, US
Platform Scientific Directors
Daniel Globisch (UU) – ADME of Therapeutics
Helena Danielson (UU) – Biophysical Screening and Characterization
Mats Persson (KI) – Display and Selection Technologies
Mats Ohlin (LU) – Display and Selection Technologies
Anders Karlén (UU) – Medicinal Chemistry (Lead Identification)
Per-Åke Nygren (KTH) – Therapeutic Protein Engineering
Pär Mattson (GU) – Oligonucleotide Therapeutics
Jens Carlsson (UU) – Computational Medicinal Chemistry
Christel Bergström (UU) – ADME of Therapeutics
Lena Friberg (UU) – ADME of Therapeutics
Mikael Altun (KI) – Biochemical and Cellular Assays
The Drug Discovery & Development platform (DDD) works together with principal investigators (PIs) primarily at Swedish universities to generate prototype drugs based on their proposed therapeutic concept.
We offer industry-standard infrastructure, expertise, and strategic support for technology development or to help progress projects towards a preclinical proof-of-concept. We work with small molecules, human antibodies, oligonoucleotides and new modality therapeutics for polypharmacology and cell therapeutics.
Calls for projects now open! Call closes October 19 2026
Through the Enabling Drug Discovery (EDD) initiative, the combined capabilities of SciLifeLab DDD, CBCS and MAX IV offer academic researchers an integrated workflow for early-stage target-based drug discovery. The support includes expert support on assay design, technology transfer and hit verification, together with access to complementary discovery approaches.
Consultation meetings in matters related to Drug Discovery (unit TPP&DSA)
Access to and logistics solution for compound management (units MCH2L and MCLI in collaboration with Chemical Biology Consortium Sweden)
A first draft for Target Product Profile (unit TPP&DSA in collaboration with RISE, Södertälje for Drug Discovery Toxicology)
Protein production for assay development and therapeutic proteins (unit TPE)
Cell Line Development in CHOZN® GS-/- and CHOZN® CHO-K1 cell lines from Merck Life Science
Selections of protein/peptide ligands made in phage display libraries of antibody fragments (units D&S and TPE)
Selections of small molecule ligands made in DNA encoded compound libraries (units MCLI and TPE)
Medicinal synthetic and computational chemistry (units MCH2L and MCLI)
Medicinal synthetic chemistry for oligonucleotide chemistry (unit ON_Chem)
Design and screening of oligonucleotide libraries (unit ON_Bio)
Analysis of drug metabolism and pharmacokinetics data (unit ADMEoT)
Assay development and establishment of structure activity relation (SAR) in primary assays (units BCA and ON_Bio)
Biophysical and structural studies of ligands to target molecules (unit BSC)
Advice on design of preclinical proof of concept studies, PK and PK/PD studies (units TPP&DSA and ADMEoT)
Swedish academic users pay for consumables. A full-cost model is applied for industry and international academic users. DDD programs are prioritized biannually by the DDD national steering board. DDD service projects (commissioned research) can be taken in when spare resources are available at the platform and decisions on inclusion are taken by the DDD management team biweekly. Importantly, the researcher/customer retains all rights and ownership during this process.
For the latest updates, please follow us on LinkedIn.
“SciLifeLab Drug Discovery & Development project owner and SciLifeLab board member Professor Fredrik Elinder was interviewed in the ionchannellibrary. He outlines the challenge of undertaking and funding drug discovery efforts in academia, the need for high-throughput ion channel measurements, and ultramarathons – all in one place.
Fredrik Elinder and Malin Silverå Ejneby in the lab. Photo: Linkoping University.
Bridge collaboration project on cell line development
During the past two years, the DDD platform has been driving the Bridge Sweden project together with Testa Center and Stuns, among others, funded by Vinnova. In the context of the Bridge Sweden project, the DDD platform acquired CHOZN® GS-/- and CHOZN® CHO-K1 cell lines from Merck Life Science, which enables us to offer cell line development to our academic users. We can offer mini pools, produce GLP-grade tox batches and select GMP-ready high producing clones using the Cytena Up.Sight instrument. This strengthens our ability to support projects from discovery through to clinical material. Read more under the TPE unit or on the BRIDGE Sweden LinkedIn page.
DDD employee Niklas Berndt Thalén opening the liquid nitrogen storage vessel for cells at SciLifeLab
Achievements, testimonials and exits
Achievements and Testimonials
“We couldn’t have done this project without SciLifeLab. To begin with, we didn’t even know which things we didn’t know, so to speak. Nor did we have the funds to be able to do it ourselves. The vast competence of the DDD platform scientists has been invaluable to us.”
Olle Hernell (Umeå University)
“To have access to the expertise and techniques provided by the DDD was critical for us in order to be able to advance our research.”
A paper titled “An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies” was recently published in Advanced Therapeutics, with many contributors from the DDD Platform. This work was the result of a successful project owned by Sara Mangsbo and her colleagues, which made an exit in 2021.
Other recent papers of interest:
Izadi A, Karami Y, Bratanis E, Wrighton S, Khakzad H, Nyblom M, Olofsson B, Happonen L, Tang D, Sundwall M, Godzwon M, Chao Y, Toledo AG, Schmidt T, Ohlin M, Nilges M, Malmström J, Bahnan W, Shannon O, Malmström L, Nordenfelt P. The hinge-engineered IgG1-IgG3 hybrid subclass IgGh47 potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies. Nat Commun. 2024 Apr 27;15(1):3600.
Sarén, T., Saronio, G., Marti Torrell, P. et al. Complementarity-determining region clustering may cause CAR-T cell dysfunction. Nat Commun14, 4732 (2023).
Luttens, A., Gullberg, H., Abdurakhmanov, E., et al. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. JACS 144, 7 (2022).
At SciLifeLab, we use necessary cookies to ensure that the website works properly for you. We also want to use cookies for web analytics to help us improve the website. You can change your cookie settings at any time. How we use cookies
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.